
## Hua Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1384271/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risk of overactive bladder associated with cholinesterase inhibitors in dementia. Journal of the American Geriatrics Society, 2022, 70, 820-830.	1.3	1
2	Opioid prescribing and prescription monitoring program use after buprenorphine discontinuation. JACCP Journal of the American College of Clinical Pharmacy, 2022, 5, 157-162.	0.5	0
3	Self-reported hay fever diagnosis and associations with sociodemographic characteristics among adults and children in the United States. Bulletin of the National Research Centre, 2022, 46, .	0.7	о
4	Evaluating adherence to concomitant diabetes, hypertension, and hyperlipidemia treatments and intermediate outcomes among elderly patients using marginal structural modeling. Pharmacotherapy, 2022, 42, 518-528.	1.2	1
5	Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study. Drugs and Aging, 2022, 39, 453-465.	1.3	4
6	Association of Puberty Stage and Weight Status with Cardiometabolic Risk in Children and Adolescents Living on the Texas-Mexico Border. Metabolic Syndrome and Related Disorders, 2022, 20, 440-450.	0.5	2
7	Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 829-836.	0.7	6
8	Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder. International Journal of Geriatric Psychiatry, 2021, 36, 684-696.	1.3	8
9	Association of the Healthcare Effectiveness Data and Information Set (HEDIS) Follow-Up Care Measures and Medication Adherence Among Medicaid Insured Children with ADHD. Journal of Attention Disorders, 2021, , 108705472098692.	1.5	0
10	Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study. Drugs and Aging, 2021, 38, 493-502.	1.3	2
11	Comparative treatment effectiveness of oral fingolimod and conventional injectable diseaseâ€modifying agents in multiple sclerosis. Pharmacotherapy, 2021, 41, 440-450.	1.2	1
12	Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Current Medical Research and Opinion, 2021, 37, 1303-1313.	0.9	3
13	Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis. Exploratory Research in Clinical and Social Pharmacy, 2021, 2, 100021.	0.6	Ο
14	Utilization of opioid versus nonâ€opioid analgesics in Medicaid and CHIP enrolled children with current asthma. Pharmacoepidemiology and Drug Safety, 2021, 30, 1520-1531.	0.9	1
15	Association of Primary and Behavioral Health Integrated Care Upon Pediatric Mental Disorder Treatment. Academic Pediatrics, 2021, 21, 1187-1194.	1.0	1
16	Switching pharmacies leads to gaps in medication possession in individuals treated with buprenorphine. Journal of the American Pharmacists Association: JAPhA, 2021, 61, 589-595.	0.7	6
17	Impact of geographic access to primary care providers on pediatric behavioral health screening. Preventive Medicine, 2021, 153, 106856.	1.6	4
18	Anticholinergic burden and risk of cognitive impairment in elderly nursing home residents with depression. Research in Social and Administrative Pharmacy, 2020, 16, 329-335.	1.5	16

#	Article	lF	CITATIONS
19	Patient-reported outcomes in light of supportive medications in treatment-naÃ <sup>-</sup> ve lung cancer patients. Supportive Care in Cancer, 2020, 28, 1809-1816.	1.0	2
20	Racial/ethnic differences in treatment quality among youth with primary care providerâ€initiated versus mental health specialistâ€initiated care for major depressive disorders. Child and Adolescent Mental Health, 2020, 25, 28-35.	1.8	8
21	Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis. Patient Preference and Adherence, 2020, Volume 14, 2187-2199.	0.8	12
22	Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study. Journal of General Internal Medicine, 2020, 35, 2084-2093.	1.3	13
23	<p>Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson's Disease and Comorbid Depression</p> . Drug, Healthcare and Patient Safety, 2020, Volume 12, 23-30.	1.0	8
24	Impact of Chlorhexidine Bathing on Antimicrobial Utilization in Surgical Intensive Care Unit. Journal of Surgical Research, 2020, 250, 161-171.	0.8	1
25	Risk of Cardiovascular Outcomes and Antihypertensive Triple Combination Therapy Among Elderly Patients with Hypertension Enrolled in a Medicare Advantage Plan (MAP). American Journal of Cardiovascular Drugs, 2020, 20, 591-602.	1.0	3
26	Risk of Mortality Associated With Atypical Antipsychotic use: A National Cohort Study of Older Adults With Depression and Parkinson's Disease. American Journal of Geriatric Psychiatry, 2020, 28, 1079-1088.	0.6	5
27	A retrospective study of drug utilization and hospital readmissions among Medicare patients with hepatic encephalopathy. Medicine (United States), 2020, 99, e19603.	0.4	9
28	Risk factors of psychotropic polypharmacy in the treatment of children and adolescents with psychiatric disorders. Research in Social and Administrative Pharmacy, 2019, 15, 395-403.	1.5	15
29	Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson's disease. Journal of Psychiatric Research, 2019, 117, 116-121.	1.5	8
30	Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 674-683.	1.0	6
31	Medication Adherence to Antihypertensive Triple-Combination Therapy Among Patients Enrolled in a Medicare Advantage Plan. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 678-686.	0.5	14
32	Reversibility of psychotropic medication induced weight gain among children and adolescents with bipolar disorders. Psychiatry Research, 2019, 276, 151-159.	1.7	9
33	The association between geographic access to providers and the treatment quality of pediatric depression. Journal of Affective Disorders, 2019, 253, 162-170.	2.0	11
34	Quality indicators to measure the effect of opioid stewardship interventions in hospital and emergency department settings. American Journal of Health-System Pharmacy, 2019, 76, 225-235.	0.5	23
35	Physician Care Coordination and the Use of Psychotropic Polypharmacy in the Management of Pediatric Mental Disorders. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 29-38.	0.5	6
36	<p>Assessment of sexually transmitted disease/HIV risk among young African Americans: comparison of self-perceived and epidemiological risks utilizing ecodevelopmental theory</p> . HIV/AIDS - Research and Palliative Care, 2019, Volume 11, 31-44.	0.4	9

#	Article	IF	CITATIONS
37	The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer, 2019, 125, 1155-1162.	2.0	72
38	Estimated Clinical and Economic Impact through Use of a Novel Blood Collection Device To Reduce Blood Culture Contamination in the Emergency Department: a Cost-Benefit Analysis. Journal of Clinical Microbiology, 2019, 57, .	1.8	24
39	Racial/ethnic differences in the treatment of adolescent major depressive disorders (MDD) across healthcare providers participating in the medicaid program. Journal of Affective Disorders, 2018, 235, 155-161.	2.0	5
40	HIV-related sexual decisions made by African-American adolescents living in different family structures: study from an ecodevelopmental perspective. HIV/AIDS - Research and Palliative Care, 2018, Volume 10, 19-31.	0.4	2
41	The impact of concomitant use of tyrosine kinase inhibitors and proton pump inhibitors on survival in older adults with cancer Journal of Clinical Oncology, 2018, 36, e18732-e18732.	0.8	0
42	Care Provision and Prescribing Practices of Physicians Treating Children and Adolescents With ADHD. Psychiatric Services, 2017, 68, 681-688.	1.1	25
43	Risk of Mortality in Elderly Nursing Home Patients with Depression Using Paroxetine. Pharmacotherapy, 2017, 37, 287-296.	1.2	9
44	Effect of Psychopharmacotherapy on Body Mass Index Among Children and Adolescents with Bipolar Disorders. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 349-358.	0.7	13
45	The Prevalence of and Factors Associated With Receiving Concurrent Controlled Substance Prescriptions. Substance Use and Misuse, 2017, 52, 1639-1645.	0.7	10
46	The Impact of Pharmacotherapy on Substance Use in Adolescents With Attention-Deficit/Hyperactivity Disorder: Variations Across Subtypes. Substance Use and Misuse, 2017, 52, 1266-1274.	0.7	8
47	Risk of Mortality Associated with Anticholinergic Use in Elderly Nursing Home Residents with Depression. Drugs and Aging, 2017, 34, 691-700.	1.3	21
48	Comparison of Suicide Attempts/Behaviors Following Smoking Cessation Treatments Among Schizophrenic Smokers. Archives of Psychiatric Nursing, 2017, 31, 62-67.	0.7	1
49	Modeling ecodevelopmental context of sexually transmitted disease/HIV risk and protective behaviors among African-American adolescents. HIV/AIDS - Research and Palliative Care, 2017, Volume 9, 119-135.	0.4	5
50	Anticholinergic Medication Use and Risk of Fracture in Elderly Adults with Depression. Journal of the American Geriatrics Society, 2016, 64, 1492-1497.	1.3	28
51	Anticholinergic Medication Use and Risk of Pneumonia in Elderly Adults: A Nested Case–Control Study. Journal of the American Geriatrics Society, 2016, 64, 394-400.	1.3	41
52	Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 395-404.	0.9	8
53	Comparative Effectiveness of Smoking Cessation Medications to Attenuate Weight Gain Following Cessation. Substance Use and Misuse, 2016, 51, 586-597.	0.7	9
54	Comparative Effectiveness of Second-Generation Antidepressants in Reducing the Risk of Dementia in Elderly Nursing Home Residents with Depression. Pharmacotherapy, 2016, 36, 38-48.	1.2	7

#	Article	IF	CITATIONS
55	Comparative risk of hip fractures in elderly nursing home patients with depression using paroxetine and other selective serotonin reuptake inhibitors. Journal of Comparative Effectiveness Research, 2016, 5, 461-473.	0.6	6
56	Prevalence and Factors Associated with Multiple Provider Episodes in Texas: An Epidemiological Analysis of Prescription Drug Monitoring Program Data. Pain Medicine, 2016, 18, pnw250.	0.9	3
57	Anticholinergic Medication Use and Risk of Dementia Among Elderly Nursing Home Residents with Depression. American Journal of Geriatric Psychiatry, 2016, 24, 485-495.	0.6	24
58	Comparative Cognitive Profile of Second-Generation Antidepressants in Elderly Nursing Home Residents With Depression. Annals of Pharmacotherapy, 2016, 50, 96-105.	0.9	3
59	Risk of Cognitive Decline Associated With Paroxetine Use in Elderly Nursing Home Patients With Depression. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 678-686.	0.9	10
60	Anticholinergic drugs and health-related quality of life in older adults with dementia. Journal of the American Pharmacists Association: JAPhA, 2015, 55, 282-287.	0.7	10
61	Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia inÂPatients with Type 2 Diabetes andÂHypertension. Journal of Alzheimer's Disease, 2015, 49, 423-432.	1.2	23
62	Concurrent Use of Stimulants and Second-Generation Antipsychotics Among Children With ADHD Enrolled in Medicaid. Psychiatric Services, 2015, 66, 404-410.	1.1	22
63	Risk of Dementia Among Elderly Nursing Home Patients Using Paroxetine and Other Selective Serotonin Reuptake Inhibitors. Psychiatric Services, 2015, 66, 1333-1340.	1.1	18
64	Antipsychotic Use and Risk of Nursing Home Admission Among Dual-Eligible Medicare Beneficiaries: A Propensity-Matched Study. Drugs - Real World Outcomes, 2015, 2, 61-71.	0.7	0
65	Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study. Drugs and Aging, 2015, 32, 743-754.	1.3	11
66	The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis. Breast Cancer Research and Treatment, 2015, 153, 591-597.	1.1	26
67	Comparison of Diabetes Risk Following Smoking Cessation Treatment Using Varenicline Versus Bupropion Among Obese Smokers. Substance Use and Misuse, 2015, 50, 1628-1637.	0.7	2
68	Risk of Hospitalization and Use of First- Versus Second-Generation Antipsychotics Among Nursing Home Residents. Psychiatric Services, 2014, 65, 781-788.	1.1	11
69	Risk of Manic Switch Associated with Antidepressant Therapy in Pediatric Bipolar Depression. Journal of Child and Adolescent Psychopharmacology, 2014, 24, 551-561.	0.7	14
70	Comparative effectiveness of monotherapy with mood stabilizers versus second generation (atypical) antipsychotics for the treatment of bipolar disorder in children and adolescents. Pharmacoepidemiology and Drug Safety, 2014, 23, 299-308.	0.9	10
71	Prevalence and Determinants of Anticholinergic Medication Use in Elderly Dementia Patients. Drugs and Aging, 2013, 30, 837-844.	1.3	42
72	The utilization of psychopharmacological treatment and medication adherence among Medicaid enrolled children and adolescents with bipolar depression. Journal of Affective Disorders, 2013, 150, 424-429.	2.0	12

#	Article	IF	CITATIONS
73	Risk of Pneumonia in Elderly Nursing Home Residents Using Typical Versus Atypical Antipsychotics. Annals of Pharmacotherapy, 2013, 47, 464-474.	0.9	21
74	Comparative effectiveness of different angiotensin-converting enzyme inhibitors on the risk of hospitalization in patients with heart failure. Journal of Comparative Effectiveness Research, 2012, 1, 195-206.	0.6	8
75	Persistence of Stimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 139-148.	0.7	36
76	Risk of Death in Dual-eligible Nursing Home Residents Using Typical or Atypical Antipsychotic Agents. Medical Care, 2012, 50, 961-969.	1.1	26
77	Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimer's and Dementia, 2012, 8, 437-444.	0.4	61
78	Risk of Falls and Fractures in Older Adults Using Atypical Antipsychotic Agents: A Propensity Score–Adjusted, Retrospective Cohort Study. American Journal of Geriatric Pharmacotherapy, 2012, 10, 83-94.	3.0	33
79	Comparative Risk of Cerebrovascular Adverse Events in Community-Dwelling Older Adults using Risperidone, Olanzapine and Quetiapine. Drugs and Aging, 2012, 29, 807-817.	1.3	24
80	Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiology and Drug Safety, 2012, 21, 233-240.	0.9	15
81	Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: A multiple-propensity analysis. Research in Social and Administrative Pharmacy, 2012, 8, 145-156.	1.5	7
82	Risk of Serious Cardiac Events in Older Adults Using Antipsychotic Agents. American Journal of Geriatric Pharmacotherapy, 2011, 9, 120-132.	3.0	20
83	Impact of changes in reimbursement policies and institutional practice algorithm for utilization of erythropoietic-stimulating agents on treatment patterns and costs in anemic lymphoma patients. Supportive Care in Cancer, 2011, 19, 251-259.	1.0	7
84	Risk factors for dementia in patients over 65 with diabetes. International Journal of Geriatric Psychiatry, 2011, 26, 749-757.	1.3	49
85	The Definition and Prevalence of Pediatric Psychotropic Polypharmacy. Psychiatric Services, 2011, 62, 1450-1455.	1.1	34
86	Off-Label Use of Second-Generation Antipsychotic Agents Among Elderly Nursing Home Residents. Psychiatric Services, 2010, 61, 130-136.	1.1	56
87	Risk of Cerebrovascular Adverse Events in Older Adults Using Antipsychotic Agents. Journal of Clinical Psychiatry, 2010, 71, 689-698.	1.1	23
88	Correlates of HIV Knowledge and Sexual Risk Behaviors Among Female Military Personnel. AIDS and Behavior, 2010, 14, 1401-1414.	1.4	14
89	Extent of functional impairment in children and adolescents with depression. Current Medical Research and Opinion, 2010, 26, 2057-2064.	0.9	25
90	Risk of Falls and Fractures in Older Adults Using Antipsychotic Agents. Drugs and Aging, 2010, 27, 815-829.	1.3	29

#	Article	IF	CITATIONS
91	Use of Antipsychotics among Elderly Nursing Home Residents with Dementia in the US. Drugs and Aging, 2009, 26, 483-492.	1.3	97
92	Economic Benefit of Appropriate Timing of Vancomycin Prophylaxis in Patients Undergoing Cardiovascular Surgery. Pharmacotherapy, 2008, 28, 699-706.	1.2	10
93	Antipsychotic drug use among elderly nursing home residents in the United States. American Journal of Geriatric Pharmacotherapy, 2008, 6, 187-197.	3.0	93
94	Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. American Journal of Geriatric Pharmacotherapy, 2008, 6, 198-204.	3.0	30
95	Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996–2004. Current Medical Research and Opinion, 2008, 24, 709-716.	0.9	22
96	The Impact of Medicare Part D on Psychotropic Utilization and Financial Burden for Community-Based Seniors. Psychiatric Services, 2008, 59, 1191-1197.	1.1	27
97	Datapoints: Antipsychotic Utilization and Expenditure Trends Among Elderly Persons. Psychiatric Services, 2007, 58, 1400-1400.	1.1	7
98	The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia. Current Medical Research and Opinion, 2007, 23, 1351-1365.	0.9	14
99	High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Current Medical Research and Opinion, 2007, 23, 1057-1065.	0.9	14
100	Prevalence and factors associated with self-reported vaccination rates among US adults at high risk of vaccine-preventable hepatitis. Current Medical Research and Opinion, 2006, 22, 2489-2496.	0.9	10
101	Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. Journal of Antimicrobial Chemotherapy, 2006, 58, 645-650.	1.3	108
102	Off-Label Use of Antidepressant, Anticonvulsant, and Antipsychotic Medications Among Georgia Medicaid Enrollees in 2001. Journal of Clinical Psychiatry, 2006, 67, 972-982.	1.1	83
103	An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoepidemiology and Drug Safety, 2005, 14, 629-638.	0.9	49